James McNab - Titan Pharmaceuticals Director

TTNP Stock  USD 7.38  0.15  2.07%   

Director

Mr. James McNab Jr., is Independent Director of Titan Pharmaceuticals, Inc. Mr. Akers brings to Titan extensive executive and financial experience. As president of Bayers hematologycardiology business, he oversaw the core of Bayers specialty pharmaceuticals development, with significant products in hematology and specialty cardiology since 2014.
Age 72
Tenure 10 years
Address 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone650 244 4990
Webhttps://www.titanpharm.com
Akers also served as president and CEO of Bayer Business and Corporationrationrationrate Services and held numerous other financial and executive positions during his 37year career with the company. He has served on the boards of Haemacure Corporationrationration, POINT Biomedical Corporation and Schein Pharmaceuticals.

Titan Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.6111) % which means that it has lost $0.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0554) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2024, Return On Capital Employed is likely to grow to -7.83. In addition to that, Return On Assets is likely to grow to -2.74. At this time, Titan Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/28/2024, Non Current Liabilities Other is likely to grow to about 1 M, while Liabilities And Stockholders Equity is likely to drop slightly above 3.5 M.
The company currently holds 187 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Titan Pharmaceuticals has a current ratio of 3.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Titan Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Titan Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Titan Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Titan to invest in growth at high rates of return. When we think about Titan Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Meryl ZausnerSeres Therapeutics
61
James DalyMadrigal Pharmaceuticals
N/A
Salvatore Falco23Andme Holding Co
46
Richard KenderSeres Therapeutics
62
Roy Blom23Andme Holding Co
65
Carina Olofsson23Andme Holding Co
42
Kurt GravesSeres Therapeutics
50
Bo Eriksson23Andme Holding Co
65
Vincenzo Capizzi23Andme Holding Co
N/A
Heidi KunzAgilent Technologies
66
Bruce KovnerMadrigal Pharmaceuticals
69
Anders Forseback23Andme Holding Co
N/A
Staffan Gavel23Andme Holding Co
67
Richard LevyMadrigal Pharmaceuticals
60
Donald KufeMadrigal Pharmaceuticals
69
Sue RatajAgilent Technologies
63
Robert WilsonMadrigal Pharmaceuticals
75
Tadataka YamadaAgilent Technologies
74
Werner CautreelsSeres Therapeutics
N/A
Helena Herlogsson23Andme Holding Co
N/A
Willard DereSeres Therapeutics
64
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. The company was incorporated in 1992 and is based in South San Francisco, California. Titan Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. Titan Pharmaceuticals (TTNP) is traded on NASDAQ Exchange in USA. It is located in 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 4 people. Titan Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Titan Pharmaceuticals Leadership Team

Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Rubin, Executive Chairman of the Board
Rajinder Kumar, Director
Brian Crowley, Senior Administration
Sunil Bhonsle, President, Secretary and Director
James McNab, Director
Federico Recli, Director
David MacFarlane, Independent Director
Joseph Akers, Director
Eurelio Cavalier, Independent Director
Marc MD, Ex Director
David Lazar, Principal Officer
Scott Smith, Director
Joe Schrei, Executive Operations
Katherine BeebeDeVarney, COO President
Ley Smith, Independent Director
Dane Hallberg, Executive Vice President and Chief Commercial Officer
Jennifer Kiernan, Executive Coordinator
Victor Bauer, Independent Director
Seghi Recli, Lead Director
Mike Fritz, National Director

Titan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Titan Stock analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.20)
Revenue Per Share
0.409
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.61)
Return On Equity
(1.06)
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.